FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	SERIAL NO.	10/587,823
	FILING DATE	December 20, 2006
	APPLICANT	Mercep et al.
	GROUP	1624
	EXAMINER	N.E. Jarrell
	ATTORNEY DOCKET NO.	PLP537USw

U.S. PATENT DOCUMENTS

Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
	1	3,773,940	Nov. 20, 1973	Schindler et al.			
	2	3,781,294	Dec. 25, 1973	Lombardino			
	3	3,859,439	Jan. 7, 1975	Blattner et al.			
	4	4,112,110	Sept. 15, 1978	Blattner			
	5	4,145,434	Mar. 20, 1979	van der Burg et al.			
	6	4,267,184	May 12, 1981	Cherkofsky et al.			
	7	4,267,190	May 12, 1981	Cherkofsky et al.			
	8	4,271,179	June 2, 1981	van der Burg			
	9	6,511,976	Jan. 28, 2003	Andres-Gil et al.			
	10	2005/0148578	July 7, 2005	Mercep et al.			

Continue on page ____

FOREIGN PATENT DOCUMENTS

		Document Number	Publication Date	Country	Class	Subclass	Translation Yes | No
	11	EP 0063525	Oct. 27, 1982	EUROPE			X
	12	EP 0125484	Nov. 21, 1984	EUROPE			
	13	EP 0357126	Mar. 7, 1990	EUROPE			
	14	EP 0372445	June 13, 1990	EUROPE			
	15	WO 91/18885	Dec. 12, 1991	WIPO			
	16	WO 96/14320	May 17, 1996	WIPO			
	17	WO 96/14321	May 17, 1996	WIPO			
	18	WO 98/54186	Dec. 3 1998	WIPO			
	19	WO 03/097648	Nov. 27, 2003	WIPO			

Continue on page ____

OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)

	20	Andres J.I., et al. "R107500. A New 5-HT 2A/2C Antagonist With Potential Anxiolytic Profile." Drugs Fut., 2002, vol. 27, Suppl. A:C41.
	21	Bennett et al. "Reaction of 5-acetyl-10, didehydro-5H-dibenz[b,f] azepine with pyrrole, N-methylpyrrole, imadazole and n-methylimidazole: cycloaddition versus Michael addition." J. Heterocycl. Chem., 1994, 31:293-296.
	22	Berge S.M., et al. "Pharmaceutical Salts." Journal of Pharmaceutical Sciences, 1977, vol. 66, pgs. 1-20.
	23	Bonhaus D.W., et al. "The Pharmacology and Distribution of Human 5-hydroxytrptamine 2B (5hT2B) Receptor Gene Products; Comparison With 5-HT2A and 5HT2C Receptors." British Journal of Pharmacology, 1995, vol. 115, pgs. 622-628.
	24	Bymaster F., et al. "New Approaches to Developing Antidepressants By Enhancing Monoaminergic Neurotransmission." Expert Opinion Investig. Drugs, 2003, 12, pgs. 531-543.
	25	Cid J.M., et al. "Synthesis Of 2-Aminomethyl-3, 3a, 8, 12." Drugs Fut., 2002, vol. 27, Suppl. A:P182.
	26	Claghorn J., et al. "Recent Developments In Antidepressant Agents." Progress in Drug Research Clinic Inc., 1996, vol 46, pgs. 243-262.
	27	Funke et al. "Physico-chemical properties and stability of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1-dibenz[2,3:6,7]oxepino[4,5-c]pyrrolidine Maleate. Arzeim-Forsch., 1190, 40:536-539.
	28	Huff, J.R. "HIV Protease: A novel chemotherapeutic target for AIDS." Journal of Medicinal Chemistry, 34(8), pgs. 2305-2314.
	29	Meert T.F., et al. "Psychopharmacology Of Ritanserin: Comparison With Chlordiazepoxide." Drug Development Research, 1989, vol. 18, pgs. 119-144.
	30	Millan M.J., et al. "S18126 ({2-4-2,3-dihydrobenzol(1,4) dioxin-6-yl)piperazin-1-ylmethyl}), A Potent, Selective and Competitive Antagonist at Dopamine D4 Receptors: An in vitro and in vivo Comparison with L 745,870 (3-(4-(4-chlorophenyl)piperazin-1-yl)methyl-1H-pyrrolo[2,3b]pyridine) and Raclopride." Journal of Pharmacology and Experimental Therapeutics, 1998, vol. 287, no. 1, pgs. 167-186.
	31	Monnet F.P., et al. "N-Methyl-D-Aspartate-Induced Neuronal Activation Is Selectively Modulated by σ Receptors." European Journal of Pharmacology, 1990, vol. 179, pgs. 441-445.

	32	Niemegeers C.J.E., et al. "Interaction Of Drugs With Apomorphine, Tryptamine And Norepinephrine. A New "In Vivo" Approach: The ATN-Test In Rats." Arch. Int. Pharmacodyn., 1977, vol. 227, pgs. 238-253.
	33	Novacek et al. "Reaction of 8-chloro-10-phenylhydrazono-10, 11-dihydro-dibenzo[b,f]thepine with aromatic aldehydes." Collection Czechoslov. Chem. Commun., 1976, Vol. 41, 785-787.
	34	Olivera et al. "Dibenzoxepino '4,5-d pyrazoles: a facile approach via the Ullman-ether reaction." Tetrahedron Letters, 2000, 41(22):4353-4360.
	35	Porsolt R.D., et al. "Behavioural Despair in Mice: A Primary Screening Test For Antidepressants." Arch. Int. Pharmacodyn., 1977, vol. 229, pgs. 327-336.
	36	Saucier C., et al. "Identification of An Endogenous 5-Hydroxytryptamine 2A Receptor in NIH-3T3 Cells: Agonist-Induced Down-Regulation Involves Decreases in Receptor RNA and Number." Journal of Neurochemistry, 1997, vol. 68, no. 1, pgs. 1998-2011.
	37	Schulz et al. "Synthese von 1,3a,3,12b-tetrahydro-dibenzo[b,f]-pyrazolo[3,4-d]azepin-Derivaten." Z. Chem. 1988, 28:181-182.
	38	Smrz, R., et al. "Neurotropic and psychotropic agents. CIII. 2(8)-chloro-10(11)- (dimethylamino)dibenzo[b,f] thiepins as potential CNS agents; synthesis and pharmacological screening." Chemopharma, Usti nad Labem, Czech. Collection of Czechoslavak Chemical Communications, 1976, 41(11), 3420-3436.
	39	Spampinato U., et al. "Role of Striata Serotonin 2A and Serotinin 2C Receptor Subtypes in the Control of In Vivo Dopamine Outflow in the Rat Striatum." J. Neurochemistry, 2000, vol. 74, pgs. 693-701.
	40	Thomson W., et al. "Juvenile Idiopathic Arthritis Genetics – What's New? What's Next? Arthritis Research, 2002, vol. 4 and 5, pgs. 302-306.
	41	Wolf W.A., et al. "The Serotonin 5-HT 2C Receptor Is A Prominent Serotinin Receptor In Basal Ganglia: Evidence From Functional Studies On Serotonin-Mediated Phosphoinositide Hydrolysis." Journal of Neurochemistry, 1997, vol. 69, pgs. 1449.

Continue on page ___

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.